An Outcomes Study Comparing the Intralase FS 60 to the Intralase iFS When Performing LASIK Surgery for Nearsightedness

Sponsor
Stanford University (Other)
Overall Status
Completed
CT.gov ID
NCT01365728
Collaborator
(none)
61
1
92
0.7

Study Details

Study Description

Brief Summary

The purpose of the study is to compare the results of LASIK surgery when using two versions of a femtosecond laser in patients with nearsightedness with and without astigmatism.

Condition or Disease Intervention/Treatment Phase
  • Procedure: LASIK with the iFS femtosecond laser

Detailed Description

The patients will have a comprehensive eye examination once they express an interest in the study. This includes a slit lamp examination of the front of the eye and a dilated fundoscopic examination of the back of the eye. If there is any pathology noted that would exclude the patient from the study, then we will inform the patient and make an appropriate referral. if the patient is deemed appropriate for the study after a comprehensive examination included computerized videokeratography, then they can be enrolled. The patient will undergo bilateral simultaneous eye surgery. Which eye is treated with the Intralase FS 60 and which eye is treated with Intralase IFS will be randomized so there is a 50% chance for either eye to receive one treatment. The patients will be seen on the day of surgery, post op day one, one month, three months, six months and one year. The patient will receive topical antibiotics in each eye for one week following the procedure. The patient will receive pred forte 1% ophthalmic drops for one week after treatment. The patient will also receive vigamox ophthalmic drops for four days after treatment. All of this is within the usual and customary standard of care for the treatment of patients undergoing LASIK surgery.

Study Design

Study Type:
Observational
Actual Enrollment :
61 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
A Prospective Randomized Comparison of Fellow Eyes Undergoing LASIK With the Intralase FS 60 Versus the Intralase IFS
Actual Study Start Date :
Apr 1, 2011
Actual Primary Completion Date :
Dec 1, 2018
Actual Study Completion Date :
Dec 1, 2018

Outcome Measures

Primary Outcome Measures

  1. Changes in Best Spectacle Corrected Visual Acuity [One year]

  2. Changes in 5% low contrast best corrected visual acuity [One year]

  3. Changes in corneal sensation [One year]

  4. Uncorrected Visual Acuity [One year]

  5. Stability of refractive outcome [One year]

  6. Changes in 25% low contrast best corrected visual acuity [One year]

Secondary Outcome Measures

  1. Subjective Questionnaire [1 yr]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects age 21 and older with healthy eyes.

  • Nearsightedness between -0.25 diopters and -7.00 diopters with or without astigmatism of up to 3.00 diopters.

Exclusion Criteria:
  • Subjects under the age of 21.

  • Patients with excessively thin corneas.

  • Patients with topographic evidence of keratoconus.

  • Patients with ectactic eye disorders.

  • Patients with autoimmune diseases.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University School of Medicine Stanford California United States 94305

Sponsors and Collaborators

  • Stanford University

Investigators

  • Principal Investigator: Edward E. Manche, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Edward E. Manche, Professor of Ophthalmology, Stanford University
ClinicalTrials.gov Identifier:
NCT01365728
Other Study ID Numbers:
  • SU-05212011-7804
  • Stanford IRB Protocol # 21250
First Posted:
Jun 3, 2011
Last Update Posted:
Mar 7, 2019
Last Verified:
Mar 1, 2019
Keywords provided by Edward E. Manche, Professor of Ophthalmology, Stanford University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 7, 2019